Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mediwound Ltd Ord Sh
(NQ:
MDWD
)
17.69
+0.08 (+0.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mediwound Ltd Ord Sh
< Previous
1
2
Next >
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
August 15, 2023
MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
August 15, 2023
MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report Second Quarter 2023 Financial Results
August 07, 2023
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Commercial Launch of NexoBrid® in Japan
August 01, 2023
Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
July 10, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
July 03, 2023
Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
June 14, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
May 30, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report First Quarter 2023 Financial Results
May 12, 2023
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces an Additional $10 Million Award from BARDA
May 09, 2023
Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
April 26, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
March 16, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
March 16, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
March 06, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
March 02, 2023
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
February 23, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
February 07, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
February 03, 2023
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
December 29, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
December 23, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Strengthens European Presence of NexoBrid®
December 20, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
December 19, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
December 13, 2022
Exclusive marketing and distribution agreement signed with Bharat Serum and Vaccines Limited (BSV), a leading biopharmaceutical company
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces a 1-for-7 Reverse Share Split
December 05, 2022
From
MediWound Ltd.
Via
GlobeNewswire
MediWound to Report Third Quarter 2022 Financial Results
November 03, 2022
Conference Call and Webcast Scheduled for Tuesday, November 15, 2022 at 8:30 am Eastern Time
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Formation of Strategic Advisory Board
October 25, 2022
Esteemed group of industry leaders to contribute expertise and experience to MediWound’s strategic and operational activities
From
MediWound Ltd.
Via
GlobeNewswire
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
October 18, 2022
EscharEx’s promising results from the completed Phase 2 trials were highlighted
From
MediWound Ltd.
Via
GlobeNewswire
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
October 07, 2022
Gross Proceeds of $30.5 Million Raised
From
MediWound Ltd.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.